Agomelatine in treating generalized anxiety disorder

Bibliography

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edtion. American Psychiatric Publishing, Washington DC; 2013
   Google Scholar
• Behar E, DiMarco ID, Hekler EB, et al. Current theoretical models for generalized anxiety disorder : conceptual review and treatment implications. J Anxiety Disord 2009;23:1011-23
   PubMed Web of Science ®Google Scholar
• Andrews G, Hobbs MJ, Borkovec TD, et al. Generalized worry disorder: a review of DSM-IV generalized anxiety disorder and options for DSM-V. Depress Anxiety 2010;27:134-47
   PubMed Web of Science ®Google Scholar
• Carter RM, Wittchen HU, Pfister H, Kessler RC. One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample. Depress Anxiety 2001;13:78-88
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe – a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005;15:357-76
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Jacobi F, Rehm J. The size and burden of mental disorders and other disorders of the brain in Europe. Eur Neuropsychopharmacol 2011;21:655-79
   PubMed Web of Science ®Google Scholar
• Maier W, Linden M, Sartorius N. Psychische Erkrankungen in der Allgemeinpraxis. Ergebnisse und Schluβfolgerungen einer WHO Studie. Dtsch Arztebl 1996;93(18):1202-6
   Google Scholar
• Wang PS, Berglund P, Olfson M, et al. Failure and delay in initial treatment contact after first onset of mental disorders in the national comorbidity survey replication. Arch Gen Psychiatry 2005;62:603-13
   PubMed Web of Science ®Google Scholar
• Bruce SE, Yonkers KA, Otto MW, et al. Influence of psychiatric comorbidities on recovery and recurrence in GAD, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry 2005;162:1179-87
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Kessler RC, Beesdo K, et al. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 2002;63(Suppl 8):24-34
   PubMed Web of Science ®Google Scholar
• Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-5
   PubMed Web of Science ®Google Scholar
• Bandelow B, Baldwin DS, Dolberg OT, et al. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder. J Clin Psychiatry 2006;67:1428-34
   PubMed Web of Science ®Google Scholar
• Stein DJ, Fincham D, Seedat S, et al. The DSM-IV-based generalized anxiety disorder severity scale : preliminary validation using data from a trial of agomelatine versus placebo. J Nerv Ment Dis 2009;32:611-28
   Google Scholar
• Allgulander C. Generalizeed anxiety disorder : between now and DSM-V. Psychiatr Clin North Am 2009;32:611-28
   PubMed Web of Science ®Google Scholar
• Hidalgo RB, Tupler LA, Davidson JR. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol 2007;21:864-72
   PubMed Web of Science ®Google Scholar
• Hoyer J, Gloster AT. Psychotherapy for generalized anxiety disorder : don't worry, it works. Psychiatr Clin North Am 2009;32:629-40
   PubMed Web of Science ®Google Scholar
• Meyer T, Miller ML, Metzger R, Borkovec TD. Development and validation of the Penn State Worry Scale. Behav Res Ther 1990;28(6):487-95
   PubMed Web of Science ®Google Scholar
• Lydiard RB, Rickels K, Herman B, Feltner DE. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmcol 2010;13:229-41
   PubMed Web of Science ®Google Scholar
• De Bodinat C, Guardiola-Lemaitre B, Mocaer E, et al. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 2010;9(8):628-42
   PubMed Web of Science ®Google Scholar
• Papp M, Litwa E, Gruca P, Mocaër E. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav Pharmacol 2006;17:9-18
   PubMed Web of Science ®Google Scholar
• Millan MJ, Brocco M, Gobert AM, Dekeyne A. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology 2005;177:448-58
   PubMed Web of Science ®Google Scholar
• Tuma J, Strubbe JH, Mocaër E, Koolhaas JM. Anxiolytic-like action of the antidepressant agomelatine (S 20098) after a social defeat requires the integrity of the SCN. Eur Neuropsychopharmacol 2005;15:545-55
   PubMed Web of Science ®Google Scholar
• Conboy L, Tanrikut C, Zoladz PR, et al. The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats. Int J Neuropsychopharmacol 2009;12:329-41
   PubMed Web of Science ®Google Scholar
• Diaz-Mataix L, Mocaër E, Seguin L, LeDoux JE. Agomelatine reduces fear long term memory but not acquisition or short term fear memories. Involvement of melatonergic and 5HT2C receptors. Abstract, ECNP 2013
   Google Scholar
• Kasper S, Hajak G, Wulff K, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized double-blind comparison with sertraline. J Clin Psychiatry 2010;71(2):271-80
   Google Scholar
• Demyttenaere K. Agomelatine : a narrative review. Eur Neuropsychopharmacol 2011;21:S703-9
   PubMed Web of Science ®Google Scholar
• Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder : a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008;28:561-6
   PubMed Web of Science ®Google Scholar
• Stein DJ, Marquez MS, Höschl C, et al. Agomelatine in generalized anxiety disorder : an active comparator and placebo-controlled study. J Clin Psychiatry 2014, doi: 10.4088/JCP.13m08433
   Web of Science ®Google Scholar
• Stein DJ, Ahokas A, Albarran C, et al. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. J Clin Psychiatry 2012;73(7):1002-8
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. American Psychiatric Publishing, Washington DC; 2000
   Google Scholar
• Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl 20):22-33
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology. NIMH, Rockville, Maryland; 1976
   Google Scholar
• Parrott AC, Hindmarch I. Factor analysis of a sleep evaluation questionnaire. Psychol Med 1978;8(2):325-9
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996;11(Suppl 3):89-95
   PubMed Web of Science ®Google Scholar
• Pollack M, Kinrys G, Krystal A, et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry 2008;65:551-62
   PubMed Web of Science ®Google Scholar
• Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep 2005;28:187-93
   PubMed Web of Science ®Google Scholar